A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab.
10.5045/kjh.2006.41.3.215
- Author:
So Yeon OH
1
;
Moon Ju JANG
;
Sei Kyung CHANG
;
Doyeon OH
;
So Young CHONG
Author Information
1. Department of Internal Medicine, Pochon CHA University College of Medicine, Seongnam, Korea. sychong@cha.ac.kr
- Publication Type:Case Report
- Keywords:
Mantle cell lymphoma;
Hyper-CVAD;
Rituximab;
Autologous stem cell transplantation
- MeSH:
Drug Therapy;
Humans;
Lymphoma, Mantle-Cell*;
Lymphoma, Non-Hodgkin;
Stem Cell Transplantation*;
Stem Cells*;
Survival Rate;
Rituximab
- From:Korean Journal of Hematology
2006;41(3):215-219
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab.
